0000899243-16-033196.txt : 20161110
0000899243-16-033196.hdr.sgml : 20161110
20161110171106
ACCESSION NUMBER: 0000899243-16-033196
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20161109
FILED AS OF DATE: 20161110
DATE AS OF CHANGE: 20161110
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Prothena Corp plc
CENTRAL INDEX KEY: 0001559053
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 25-28 NORTH WALL QUAY
CITY: DUBLIN
STATE: L2
ZIP: DUBLIN 1
BUSINESS PHONE: 650-615-2119
MAIL ADDRESS:
STREET 1: 25-28 NORTH WALL QUAY
CITY: DUBLIN
STATE: L2
ZIP: DUBLIN 1
FORMER COMPANY:
FORMER CONFORMED NAME: Neotope Corp Ltd
DATE OF NAME CHANGE: 20120926
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kinney Gene G.
CENTRAL INDEX KEY: 0001564380
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35676
FILM NUMBER: 161989083
MAIL ADDRESS:
STREET 1: C/O PROTHENA CORPORATION PLC
STREET 2: 650 GATEWAY BOULEVARD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2016-11-09
0
0001559053
Prothena Corp plc
PRTA
0001564380
Kinney Gene G.
C/O PROTHENA BIOSCIENCES INC
650 GATEWAY BOULEVARD
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
President and CEO
Ordinary Shares, par value $0.01 per share
2016-11-09
4
M
0
8548
6.41
A
11341
D
Ordinary Shares, par value $0.01 per share
2016-11-09
4
S
0
8548
55.3235
D
2793
D
Stock Option (right to buy)
6.41
2016-11-09
4
M
0
8548
0.00
D
2023-01-29
Ordinary Shares
8548
140833
D
The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person.
The transaction was executed in multiple trades in prices ranging from $55.00 to $55.90, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on January 29, 2014 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
/s/ A.W. Homan, as Attorney-in-Fact for Gene G. Kinney
2016-11-10